Table 4 Univariate and multivariate analysis of risk factor for infectious and non-infectious pulmonary toxicity
Infectious | Non-infectious | |||||
|---|---|---|---|---|---|---|
SHR | 95% CI | P-value | SHR | 95% CI | P-value | |
Univariate analysis | ||||||
Group | ||||||
Reduced dose rate group | 1 (ref) | 1 (ref) | ||||
Conventional dose rate group | 1.77 | 0.81–3.85 | 0.153 | 4.06 | 0.90–18.28 | 0.068 |
Total dose (Gy) | 1.38 | 1.02–1.87 | 0.038 | 0.83 | 0.55–1.26 | 0.381 |
Daily dose (Gy) | ||||||
Daily dose < 3 | 1 (ref) | 1 (ref) | ||||
Daily dose ≥3 | 0.52 | 0.25–1.10 | 0.087 | 0.68 | 0.37–1.22 | 0.201 |
Women | 1.22 | 0.64–2.34 | 0.545 | 1.10 | 0.35–3.44 | 0.871 |
Age at TBI (year) | 1.00 | 0.98–1.02 | 0.854 | 0.99 | 0.96–1.02 | 0.486 |
Cancer type | ||||||
ALL | 1 (ref) | 1 (ref) | ||||
AML | 1.69 | 0.87–3.31 | 0.124 | 1.40 | 0.30–6.57 | 0.668 |
Others | 1.22 | 0.48–3.09 | 0.671 | 1.26 | 0.36–4.44 | 0.718 |
Unrelated donor | 1.30 | 0.68–2.48 | 0.436 | 0.98 | 0.34–2.85 | 0.971 |
Conditioning regimen | ||||||
Cyclophosphamide | 1 (ref) | 1 (ref) | ||||
Cyclophosphamide + other* | 1.65 | 0.65–4.20 | 0.290 | Cannot be calculated | Cannot be calculated | 0.921 |
Others† | 0.80 | 0.29–2.19 | 0.659 | Cannot be calculated | Cannot be calculated | 0.925 |
Prior chemotherapy regimens | ||||||
1 | 1 (ref) | 1 (ref) | ||||
2 | 0.60 | 0.27–1.35 | 0.219 | 0.45 | 0.07–2.97 | 0.405 |
≥ 3 | 1.25 | 0.60–2.60 | 0.551 | 2.20 | 0.42–11.42 | 0.349 |
Multivariate analysis | ||||||
Group | ||||||
Reduced dose rate group | 1 (ref) | |||||
Conventional dose rate group | 2.38 | 1.02–5.54 | 0.045 | |||
Total dose (Gy) | 1.40 | 1.07–1.85 | 0.016 | |||
Daily dose (Gy) | 0.24 | 0.07–0.83 | 0.025 | |||
Cancer type | ||||||
ALL | 1 (ref) | |||||
AML | 1.69 | 0.83–3.42 | 0.146 | |||
Others | 1.41 | 0.56–3.52 | 0.463 | |||